initi coverag buy target
game-chang technolog help diabet
want improv extend life span
initi buy initi coverag nemaura medic inc
buy rate price target nmrd medic technolog compani
develop sugarbeat non-invas afford flexibl continu
glucos monitor cgm system adjunct use person
diabet sugarbeat consist dispos adhes skin-patch
connect recharg wireless transmitt display glucos
read regular five-minut interv via mobil app
world first non-invas continu glucos monitor monitor glucos
critic diabet choic finger stick need
sensor place skin day nemaura
technolog allow sensor place skin
larg billion market opportun diabet affect peopl
world type ii market type ii diabet estim
billion pre-diabet market estim billion
wearabl health-tech/biohack market estim billion
believ fastest grow adopt group product biohack
like geoffrey woo co-found ceo hvmn hvmn com
diabet thought leader biohack movement
voluntarili wear compet invas cgm freestyl libr abbott
laboratori abt-nr order perfect bodi dorsey anoth
thought leader biohack lifestyl trend prime candid
product sugarbeat get fda approv becom avail retail
sale amazon believ substanti demand
fda approv yet geoff wait expect fda
approv next mileston compani receiv ce mark approv
may may pursu sugarbeat commerci sale
eu
execut plan ce mark approv recent achiev mileston
next mileston expect fda approv plan roll
product great britain compani locat follow europ
 technolog addit target market also pursu
includ continu lactat monitor clm aim elit athlet
train becom elit simpli want perform
current valuat attract price target deriv synthet
dividend discount model repres signific upsid current
share price believ valuat balanc compani risk
high growth prospect larg upsid opportun
base loughborough leicestershir unit kingdom nemaura medic
afford flexibl continu glucos monitor system
adjunct use person diabet
ascendi capit market llc seek busi
compani cover research team
consequ investor awar
firm may conflict interest could affect
object report investor
consid report singl factor make
invest decis
analyst certif import
disclosur refer disclosur section locat
end report begin page
initi buy initi coverag nemaura medic inc buy rate price target nmrd medic
technolog compani develop sugarbeat non-invas afford flexibl continu glucos monitor cgm system
adjunct use person diabet sugarbeat consist dispos adhes skin-patch connect recharg
wireless transmitt display glucos read regular five-minut interv via mobil app
world first non-invas continu glucos monitor monitor glucos critic diabet choic finger
stick need sensor place skin day nemaura technolog allow sensor place
larg billion market opportun diabet affect peopl world type ii market type ii diabet
estim billion pre-diabet market estim billion wearabl health-tech/biohack market
estim billion believ fastest grow adopt group product biohack like geoffrey woo co-found
 ceo hvmn hvmn com diabet thought leader biohack movement voluntarili wear
compet invas cgm freestyl libr abt-nr order perfect bodi dorsey anoth thought leader
biohack lifestyl trend prime candid product sugarbeat get fda approv becom avail retail
sale amazon believ substanti demand
fda approv yet geoff wait expect fda approv next mileston compani receiv ce
mark approv may may pursu sugarbeat commerci sale eu
execut plan ce mark approv recent achiev mileston next mileston expect fda approv plan
roll product great britain compani locat follow europ technolog addit
target market also pursu includ continu lactat monitor clm aim elit athlet train
becom elit simpli want perform best
current valuat attract price target deriv synthet dividend discount model repres signific upsid
current share price believ valuat balanc compani risk high growth prospect larg upsid
initi coverag nemaura medic buy rate price target base synthetic-
dividend discount model model target round penni compani receiv first
devic approv last month gener minim revenu signific loss tradit valuat metric use
assumpt compani continu rais capit year next three year four reach break-even
year time captur neglig share address market feel conserv valuat
model shown figur model sum earn per share discount arriv per share valu
termin valu growth assum note model underst futur novel product develop probabl underst
tax benefit offset earn never year
nmrd medic technolog compani develop sugarbeat non-invas afford flexibl continu glucos
monitor system adjunct use person diabet sugarbeat consist dispos adhes skin-patch connect
recharg wireless transmitt display glucos read regular five-minut interv via mobil app sugarbeat
work extract glucos skin chamber patch direct contact electrode-bas sensor
transmitt send raw data mobil app process algorithm display glucos read
abil track trend data day week month sugarbeat requir per day calibr patient
use blood sampl obtain finger stick believ sugarbeat adopt
non-insulin depend person diabet
biohack look follow certain lifestyl improv health life span
insulin-inject person diabet perform multipl daili finger stick manag diseas
technolog product work benefit shown figur
figur nemaura medic inc technolog work
figur nemaura medic inc benefit sugarbeat technolog
figur show sugarbeat product compar peer two main differ sugarbeat less expens
non-invas believ two trait drive adopt seek benefit lifestyl choic well diabet
peopl pre-diabet
skin
insert skin
insert skin
insert arm
dexcom user guid press releas aug dexcom user guid senseon hold dec
show figur larg market opportun diabet affect peopl world type ii market
type ii diabet estim billion pre-diabet market estim billion wearabl health-
tech/biohack market estim billion believ fastest grow adopt group product biohack like
geoffrey woo co-found ceo hvmn hvmn com geoffrey diabet thought leader biohack
movement voluntarili wear compet invas cgm freestyl libr order perfect bodi dorsey
anoth thought leader biohack lifestyl trend prime candid product sugarbeat get fda approv
becom avail retail sale amazon believ substanti demand
ce mark approv recent achiev mileston see figur next mileston expect fda approv plan
roll product great britain compani locat follow europ technolog addit target
market also pursu includ continu lactat monitor clm aim elit athlet train becom
elit simpli want perform best
complet clinic studi type type diabet subject
defin final devic claim submiss ce mark approv
scale commerci sensor/patch manufactur
ce mark bodi worn transmitt devic
scale devic transmitt manufactur
commerci launch uk follow major territori europ
diabet world-wide medic problem
accord intern diabet foundat latest data
approxim million adult year live diabet rise million
proport peopl type diabet increas countri
adult diabet live low- middle-incom countri
greatest number peopl diabet year age
million peopl diabet undiagnos
diabet caus least billion dollar health expenditur total spend adult
children live type diabet
million live birth birth affect diabet pregnanc
million peopl risk develop type diabet
around peopl diabet type diabet
type diabet caus autoimmun reaction bodi defens system attack cell produc insulin
result bodi produc littl insulin exact caus yet known link combin
genet environment condit
type diabet affect peopl age usual develop children young adult peopl type diabet need daili
inject insulin control blood glucos level peopl type diabet access insulin die
risk factor type diabet still research howev famili member type diabet slightli increas
risk develop diseas environment factor exposur viral infect also link risk
present type diabet prevent environment trigger thought gener process result
destruct bodi insulin-produc cell still investig
type diabet common form diabet around peopl diabet type diabet
gener character insulin resist bodi fulli respond insulin insulin work
properli blood glucos level keep rise releas insulin peopl type diabet eventu exhaust
pancrea result bodi produc less less insulin caus even higher blood sugar level hyperglycemia
type diabet commonli diagnos older adult increasingli seen children adolesc younger adult due
rise level obes physic inact poor diet onset diseas symptom develop mani peopl
undiagnos diabet alreadi complic chronic kidney diseas heart failur retinopathi neuropathi
earli detect diagnosi cost-effect treatment save live prevent significantli delay devast diabetes-rel
mani case type diabet prevent adopt healthi lifestyl much done improv qualiti life increas
physic activ reduc morbid mortal peopl live type diabet
figur nemaura medic inc atla diabet
nemaura intend lead discoveri develop commerci innov target diagnost medic devic
improv diseas monitor manag overal patient care specif intend focu monitor
molecul drawn skin non-invas use technolog platform addit glucos
molecul may includ lactic acid monitor monitor prescript drug alcohol blood biomark may help
diagnosi prevent manag diseas diabet see figur current plan product
pipelin nmrd plan take follow step implement broad busi strategi key commerci strategi post-
approv first implement europ part middl east asia follow
commerci sugarbeat unit kingdom republ ireland dalla burston pharma jersey limit
exclus market right agreement two countri
also sign full commerci agreement dalla burston ethitronix europ limit may european
territori part equal joint ventur agreement joint ventur intend seek sub-licens right opportun one
lead compani diabet monitor space leverag network infrastructur resourc
establish licens joint ventur agreement parti market sugarbeat geographi nmrd
detail discuss negoti sever parti world-wide licens joint ventur agreement
sale sugarbeat devic sign commerci agreement tp mena gcc gulf region al-
danah medic qatar
submit fda applic approv sugarbeat applic current progress expect submit
quarter
expand indic sugarbeat devic may use believ sugarbeat devic may offer
signific benefit compar found non-acut set monitor diseas includ
monitor lactic acid perform athlet monitor drug complet initi proof concept
lactat monitor plan explor rout commerci well-b applic athlet
perform train plan undertak clinic program support clinic use devic lactat
enhanc underli technolog platform may take form web-serv access physician
diabet profession track condit remot therebi reduc healthcar cost manag condit
effect complet virtual doctor monitor person vital sign transmit result via web
patch use technolog platform measur altern analyt includ lactat uric acid lithium drug
expand product pipelin proprietari platform technolog acquisit strateg licens
arrang nmrd intend leverag proprietari platform technolog grow portfolio product candid
diagnosi diabet diseas addit intend licens product acquir product
technolog consist research develop busi focu strategi may includ
drug deliveri product improv manag diabet exampl improv insulin injector system and/or
combin drug product diabet relat drug
note junip research digit health report jan compani present
faz chowdhuri chief execut offic dr chowdhuri serv ceo chair board nemaura medic sinc format
decemb sole inventor grant pend patent across technolog platform within
medic devic pharmaceut sector author textbook chapter nano-biosci wiley elsevi
serv board medilink east midland uk dr chowdhuri hold master microsystem nanotechnolog
cranfield univers uk doctor univers oxford nano-medicin drug deliveri
mr bashir timol chief busi offic mr timol serv member board nemaura medic sinc format
decemb cbo sinc april co-found manag fund sever biotech life scienc compani
led invest consortium provid capit initi two fund round nemaura medic mr timol obtain
bachelor art degre econom univers central lancashir uk
dr fred schaebsdau strategi busi develop advisor dr schaebsdau year execut level experi
cgm blood glucos monitor bgm insulin deliveri industri start tenur abbott
diabet member post-merg integr team respons acquisit therasens
freestyl navig cgm septemb januari gener manag dexcom germani
leadership becam fastest grow organ histori achiev tripl digit revenu new patient
growth everi year gener cgm success launch negoti public insur complet
result full reimburs german popul august roch diabet
senior vice-presid head global strategi busi develop complet sever strateg acquisit
partnership licens deal septemb found firm exclus distributor europ middl east
africa unistrip world first gener blood glucos test strip sinc septemb member advisori board
peppermint ventur partner dr schaebsdau studi medicin univers giessen complet resid urolog
surgeri univers chicago univers hannov univers freiburg licens practic medicin
 germani resid univers hannov conduct primari research neurophysiolog grant
dfg deutsch forschungsgemeinschaft complet phd receiv wharton school
univers pennsylvania
professor karrar khan director product develop professor karrar khan year experi drug discoveri
pharmaceut develop registr manag pharmaceut scientist experi includ year head
develop boot two year director osi manag
pharmaceut develop analyt oper dmpk expertis rang develop phase phase
signific experi bring prescript over-the-counter product market global level contribut registr
launch pharmaceut product qualifi person ec qualiti assur direct
david scott director commerci develop licens david scott train chemist year experi
pharmaceut industri span deal broker market strateg plan financ busi develop acquisit
skill negoti close number major deal inward outward licens pharmaceut product
deliveri system technolog also provid licens train number multi-national pharma compani
train organ publish wide author best-sel report scrip practic guid
licens david also accredit certifi licens profession
march end gross oper tax incom share compani report ascendi capit market llcfigur nemaura medic inc incom million except per share
march end sheetcurr asset account total current net non-curr total liabilitiesaccount due relat current total current total equitypref common addit retain tran adj treasuri total stockhold total liabil compani report ascendi capit market llcfigur nemaura medic inc balanc sheet million except per share
million net term due relat current common addit comp total ascendi capit market llcfigur nemaura medic inc
analyst herebi certifi view express report reflect analyst person view subject secur
issuer analyst also certifi part analyst compens directli indirectli relat
specif recommend view express report analyst prepar report compens base upon
overal profit ascendi capit market llc may time time includ provis invest
bank financi advisori consult servic compens research base effect gener new idea
client perform recommend accuraci earn estim servic client
ascendi capit market llc receiv compens advisori invest bank servic
compani past month
